Suppr超能文献

美国肝内胆管癌手术趋势及手术接受情况差异:2005 - 2014年

Trends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005-2014.

作者信息

Ransome Eke, Tong Li, Espinosa Jairo, Chou Jesse, Somnay Vishal, Munene Gitonga

机构信息

Division of Epidemiology and Biostatistics, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.

Department of General Surgery, Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, USA.

出版信息

J Gastrointest Oncol. 2019 Apr;10(2):339-347. doi: 10.21037/jgo.2018.12.07.

Abstract

BACKGROUND

Intrahepatic cholangiocarcinoma (IHC) is a malignancy with an increasing incidence. Surgery is the only treatment modality associated with long term survival. The objective of this study is to utilize a nationwide representative database to quantify the trends in incidence, and surgery for IHC in the United States from 2004-2014, as well as identify any disparities in the receipt of surgery.

METHODS

All patients admitted with a diagnosis of IHC between 2005 and 2014 were identified from the Nationwide Inpatient Sample (NIS) database. Trends in the number of IHC admissions and surgery procedures as well as outcomes were examined, and a multivariate analysis was used to determine the effects of demographic and clinical co-variables on resection rates.

RESULTS

An estimated total of 104,045 IHC related admissions occurred between 2005 and 2014. The hospitalization rate for IHC increased by nearly 2-fold in 2014 [38.9 per 100,000 (95% CI, 35.7-42.2)] from 18.1 per 100,000 (95% CI, 15.8-20.3) in 2005. Liver resections increased 248% (P<0.01) with an increasing majority being performed at teaching hospitals and 56% being minor resections. There was an increase in estimated hospital charges from $87,124 to $148,613 (P<0.001) and decrease in LOS from 12 days to 10 days (P<0.01). Inpatient mortality for IHC decreased significantly from 11% to 8.4% (P=0.004), from year 2005 to 2014 respectively. Age >80 years (OR =0.45; 95% CI, 0.33-0.60), Black race (OR =0.50; 95% CI, 0.39-063), Hispanic race (OR =0.59; 95% CI, 0.45-0.79), Medicaid insurance (OR =0.58; 95% CI, 0.42-0.79) and Elixhauser comorbidity score >3 (OR =0.58; 95% CI, 0.47-0.73) were associated with decreased rates of resection.

CONCLUSIONS

Overall hospitalization and volume of surgery for IHC has increased dramatically over the past decade. There has been an increase in cost, decrease in LOS and inpatient mortality during the period. Socioeconomic and racial disparities were observed in the receipt of surgery for IHC. Additional work is needed to understand the complex interplay between socioeconomic status and race in in the treatment of IHC.

摘要

背景

肝内胆管癌(IHC)是一种发病率不断上升的恶性肿瘤。手术是唯一与长期生存相关的治疗方式。本研究的目的是利用一个全国代表性数据库,量化2004 - 2014年美国肝内胆管癌的发病率和手术趋势,并确定手术接受方面的任何差异。

方法

从全国住院样本(NIS)数据库中识别出2005年至2014年间所有诊断为肝内胆管癌的住院患者。检查了肝内胆管癌入院人数、手术程序数量及结果的趋势,并使用多变量分析来确定人口统计学和临床协变量对切除率的影响。

结果

2005年至2014年间估计共有104,045例与肝内胆管癌相关的入院病例。2014年肝内胆管癌的住院率从2005年的每10万人18.1例(95%可信区间,15.8 - 20.3)增加到近2倍,即每10万人38.9例(95%可信区间,35.7 - 42.2)。肝切除术增加了248%(P<0.01),其中越来越多的手术在教学医院进行,56%为小范围切除。估计住院费用从87,124美元增加到148,613美元(P<0.001),住院时间从12天减少到10天(P<0.01)。从2005年到2014年,肝内胆管癌的住院死亡率分别从11%显著下降到8.4%(P = 0.004)。年龄>80岁(比值比 = 0.45;95%可信区间,0.33 - 0.60)、黑人种族(比值比 = 0.50;95%可信区间,0.39 - 0.63)、西班牙裔种族(比值比 = 0.59;95%可信区间,0.45 - 0.79)、医疗补助保险(比值比 = 0.58;95%可信区间,0.42 - 0.79)和埃利克斯豪泽合并症评分>3(比值比 = 0.58;95%可信区间,0.47 - 0.73)与较低的切除率相关。

结论

在过去十年中,肝内胆管癌的总体住院率和手术量显著增加。在此期间,费用增加,住院时间减少,住院死亡率降低。在肝内胆管癌手术接受方面存在社会经济和种族差异。需要进一步开展工作来了解社会经济地位和种族在肝内胆管癌治疗中的复杂相互作用。

相似文献

1
5
Spinal fusion for pediatric neuromuscular scoliosis: national trends, complications, and in-hospital outcomes.
J Neurosurg Spine. 2016 Oct;25(4):500-508. doi: 10.3171/2016.2.SPINE151377. Epub 2016 May 20.
7
Healthcare utilization and costs associated with cholangiocarcinoma.
Gastroenterol Rep (Oxf). 2017 Aug;5(3):213-218. doi: 10.1093/gastro/gow026. Epub 2016 Aug 10.
9
National hospital volume in acute pancreatitis: analysis of the Nationwide Inpatient Sample 1998-2006.
HPB (Oxford). 2009 Aug;11(5):391-7. doi: 10.1111/j.1477-2574.2009.00072.x.

引用本文的文献

2
Forty-five-year trends in intra- and extrahepatic cholangiocarcinoma: sex- and race-based insights.
Ann Gastroenterol. 2025 Mar-Apr;38(2):214-220. doi: 10.20524/aog.2025.0951. Epub 2025 Feb 28.
3
Care Patterns and Outcomes for Intrahepatic Cholangiocarcinoma by Rurality of Patient Residence in a Midwestern State.
J Surg Oncol. 2025 Mar;131(3):450-456. doi: 10.1002/jso.27939. Epub 2024 Oct 4.
4
Comparing Survival After Resection, Ablation, and Radiation in Small Intrahepatic Cholangiocarcinoma.
Ann Surg Oncol. 2023 Oct;30(11):6639-6646. doi: 10.1245/s10434-023-13872-y. Epub 2023 Jul 12.
5
Examining disparities among older multimorbid emergency general surgery patients: An observational study of Medicare beneficiaries.
Am J Surg. 2023 Jun;225(6):1074-1080. doi: 10.1016/j.amjsurg.2022.11.026. Epub 2022 Nov 21.
6
Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States.
Cancer. 2022 Oct;128(20):3610-3619. doi: 10.1002/cncr.34436. Epub 2022 Aug 23.
7
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link.
Ann Glob Health. 2022 Jun 13;88(1):41. doi: 10.5334/aogh.3660. eCollection 2022.
8
Prognostic factors for patients with mass-forming intrahepatic cholangiocarcinoma: A case series of 68 patients.
World J Gastrointest Surg. 2022 May 27;14(5):442-451. doi: 10.4240/wjgs.v14.i5.442.
9
Updates in Cholangiocarcinoma.
J Adv Pract Oncol. 2022 Apr;13(3):320-323. doi: 10.6004/jadpro.2022.13.3.28. Epub 2022 May 23.

本文引用的文献

1
Trends in Incidence and Factors Affecting Survival of Patients With Cholangiocarcinoma in the United States.
J Natl Compr Canc Netw. 2018 Apr;16(4):370-376. doi: 10.6004/jnccn.2017.7056.
2
Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project.
Br J Cancer. 2018 Apr;118(7):1005-1012. doi: 10.1038/s41416-018-0007-z. Epub 2018 Mar 9.
3
New Persistent Opioid Use Among Patients With Cancer After Curative-Intent Surgery.
J Clin Oncol. 2017 Dec 20;35(36):4042-4049. doi: 10.1200/JCO.2017.74.1363. Epub 2017 Oct 19.
4
NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.
J Natl Compr Canc Netw. 2017 May;15(5):563-573. doi: 10.6004/jnccn.2017.0059.
5
Patterns of hepatic resections in North America: use of concurrent partial resections and ablations.
HPB (Oxford). 2016 Oct;18(10):813-820. doi: 10.1016/j.hpb.2016.06.002. Epub 2016 Jul 21.
6
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise.
Oncologist. 2016 May;21(5):594-9. doi: 10.1634/theoncologist.2015-0446. Epub 2016 Mar 21.
7
Centralization of pancreatoduodenectomy a decade later: Impact of the volume-outcome relationship.
Surgery. 2016 Jun;159(6):1528-1538. doi: 10.1016/j.surg.2016.01.008. Epub 2016 Feb 17.
8
A nationwide population-based study shows increasing incidence of cholangiocarcinoma.
Hepatol Int. 2013 Mar;7(1):226-32. doi: 10.1007/s12072-012-9369-0. Epub 2012 May 16.
9
National trends in the use of surgery for benign hepatic tumors in the United States.
Surgery. 2015 Jun;157(6):1055-64. doi: 10.1016/j.surg.2015.01.015. Epub 2015 Mar 11.
10
Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification.
Dig Dis Sci. 2014 Dec;59(12):3103-10. doi: 10.1007/s10620-014-3276-2. Epub 2014 Sep 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验